| アブストラクト | BACKGROUND: The independent contribution of levodopa exposure and Parkinson's disease (PD) to the risk of polyneuropathy is not established. OBJECTIVE: This study investigated whether patients with newly diagnosed PD without previous exposure to antiparkinsonian drugs have higher prevalence of polyneuropathy than the general population. METHODS: Using the UK General Practice Research Database, presence of polyneuropathy in the previous 3 years was assessed. RESULTS: Of 5089 PD patients and 19,897 controls, polyneuropathy was confirmed in 15 PD patients (0.29% ) and 24 controls (0.12% ). Polyneuropathy prevalence was 2.4-fold higher in PD patients than controls. CONCLUSIONS: In this observational study, PD patients had a higher prevalence of preexisting polyneuropathy that cannot be explained by adverse effects of antiparkinsonian drugs. |
|---|
| ジャーナル名 | Journal of Parkinson's disease |
|---|
| Pubmed追加日 | 2017/11/21 |
|---|
| 投稿者 | Conradt, Christian; Guo, Dianlin; Miclea, Anca; Nisslein, Thomas; Ismail, Chaim; Chatamra, Krai; Andersohn, Frank |
|---|
| 組織名 | AbbVie Inc., North Chicago, IL, USA.;Abbott Laboratories, EDP Global Pharmacovigilance, Hannover, Germany.;PB Consulting Network, Oberpfalz, Germany.;Institute for Social Medicine, Epidemiology, and Health Economics, Charite;University Medical Center, Frank Andersohn Consulting and Research Services,;Berlin, Germany. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29154292/ |
|---|
